Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. - Wikidata - wikimedia - TriplyDB

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

http://www.wikidata.org/entity/Q39174520

about

Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy Antibody-based immunotherapy of solid cancers: progress and possibilities CD4 T-cell immunotherapy for chronic viral infections and cancer Phenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancy Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients Role of Tregs in Cancer Dormancy or Recurrence.Spontaneous restoration of transplantation tolerance after acute rejection.Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?Chronic thoracic spinal cord injury impairs CD8+ T-cell function by up-regulating programmed cell death-1 expression.Combination immunotherapy: a road map.Structure and cancer immunotherapy of the B7 family member B7x Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.An exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen.PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).Thioredoxin induces Tregs to generate an immunotolerant tumor microenvironment in metastatic melanoma.Depletion of B220(+)NK1.1(+) cells enhances the rejection of established melanoma by tumor-specific CD4(+) T cells.Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy T-cell exhaustion in the tumor microenvironment.Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer Immunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring.Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy.Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer.Emerging immune checkpoints for cancer therapy.Regulatory T cells in the immunotherapy of melanoma.Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.Functional exhaustion of CD4+ T cells induced by co-stimulatory signals from myeloid leukaemia cells.Genetic and Epigenetic Regulation of PD-1 Expression Cutting edge: epigenetic regulation of Foxp3 defines a stable population of CD4+ regulatory T cells in tumors from mice and humans.A role for pre-mNK cells in tumor progression.Making urothelial carcinomas less immune to immunotherapy.LAG3 (CD223) as a cancer immunotherapy target.

P2860

Q26742107-7A615F86-606D-4262-A37B-EB58ABCA40A4 Q26796542-E2E61D2F-40AE-4E03-A584-9FC3F21D2693 Q27022957-F8345447-B076-4E2D-A24B-3C3B1EA6E3BD Q27346770-408E114E-056B-4642-A909-EAE9E050BA95 Q28066486-89A1D316-7803-4EA3-9311-DE0C1CC3BC66 Q28068378-F8E1A1E0-3C5C-4356-AB50-943DA4D22391 Q28542660-B73478B6-67DB-41A0-8292-EB7F4E304AED Q30244203-FD552D31-0992-4A4B-AEC3-0866FDDB20E3 Q30657418-E0580235-42FC-4F5E-926D-34ECF458EE18 Q33707098-0C13DDE4-DFF7-45E4-81DD-628A708CE68C Q34259974-2F02A8DD-4449-4E67-A382-16634F951127 Q34418112-2F71BEB8-9BA3-4711-971C-37C6119AFAEB Q34505107-86B998D8-6680-4B40-90D5-EDE79B240969 Q34552128-04FDBD1E-068B-4D48-8C63-9D8385182BE0 Q34605921-820CAB5C-2D14-4029-B09E-202FB02989D5 Q35130794-BA139DEF-081C-4AA6-BEF2-25B87C8A6808 Q35431621-9B7CA832-EF07-4BF6-BF67-EC12BDEC23CE Q35688947-648A2C3F-1EAD-4D00-8B68-7966F7C6B375 Q36024656-5A6EF9B8-464E-40B2-B7B5-D96303FF2CD7 Q36060244-E66C3610-5122-4637-9B69-0980F709ABF4 Q36060315-A4FB06A3-4B10-4B70-A532-0458CEC20EB8 Q36173500-D434C963-618A-4334-8F0C-1F19B52ACBD3 Q36347369-446EF64C-0DE6-4D2E-AEDA-5604BB42D5C9 Q36639475-7E6ECA92-919E-4963-A8F7-9D412D49621C Q36954166-7350826E-B0C5-4FD4-A6D3-07F7C29EA2F3 Q37086237-A95F66F7-4B2F-4023-8DEC-C66DA63D5914 Q37290632-D1AC2CD5-77C8-4C90-81B2-C170FF1162CE Q37728543-945938CC-F3A9-4EFE-91FF-066E2A095C79 Q38154151-2E84294F-90A0-4E7F-BC86-DDF91C65C56A Q38155039-707D219A-E3FC-4377-927A-838DCB1EAB02 Q38198735-4B3BE761-4941-4334-B562-0133FB1541AF Q38584979-B37BBC77-A610-4EDD-95BB-4AA0A56CC82C Q38619815-6C5D2081-E8CF-4D17-9411-035D8EF25417 Q38636569-795BAADA-3AA7-4BFC-AE50-DE7268B38132 Q38733598-2D79EBDA-5F31-417A-9C7B-A25F51820270 Q38761535-BDA6BAD5-DBEA-424B-903A-C3BD6B9BC7F9 Q38924558-A5A9BD34-CD3E-48ED-B0FD-4380DE386B42 Q39001313-EF628123-9C35-4A49-96E8-A9D5760EFCD6 Q39005601-D7F26C4E-AA29-48EB-9422-255E74654B9A Q39160974-D9BFF7FD-1673-4A5E-8157-D907A8CFDBDF

P2860

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

http://www.wikidata.org/entity/Q39174520

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

@en

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

@nl

type

label

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

@en

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

@nl

prefLabel

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

@en

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

@nl

P1433

Q39174520-24E56EA4-865F-429B-94B3-603E09204060

P1476

Q39174520-B5C122B5-FF77-4C70-9B05-5C74F055F027

P2093

Q39174520-12B820F6-B3EF-4156-9E49-8E1E2511E1D7

Q39174520-22A27303-F451-4328-B0AC-642689F62DB7

Q39174520-2499365A-71A5-42A1-9AF0-B6B376E38D5E

Q39174520-868F2F3E-982C-4FEF-8B25-27620896BA18

Q39174520-C05B1FBE-65AB-47EB-BEC5-D89F294D51E5

Q39174520-C1B1A23F-B903-4A94-B55E-AA075C2A56F8

Q39174520-C838E506-3815-4ECC-A8E2-D5447675155D

Q39174520-CD402427-C457-4C41-AF67-60763AF43758

Q39174520-DEF0AA86-9F10-44D8-9D63-7E61EA88FE83

Q39174520-F435F5A3-1FBD-4A26-8E40-47D0A3A0E825

P2860

Q39174520-046C39DC-383D-4EB2-988E-EE9D1B6EBF80

Q39174520-05262E70-BE8B-4122-9E87-D5A55526F7DC

Q39174520-05C9CBE5-843F-484A-87E1-ECC532478BF1

Q39174520-0654AC23-EB15-4613-9080-EA3276EC65CE

Q39174520-0A92871D-D95B-405C-98FD-002BDC64B0C7

Q39174520-0F66251A-494A-4CA0-9101-176FF3014563

Q39174520-132B7EAE-2080-47D2-887B-33FB416A742C

Q39174520-1B584C5D-368A-486D-B0CF-64F2322D384D

Q39174520-1CBCE26B-CA13-43CE-85B3-82F593DF5D48

Q39174520-1DB8D224-E2CB-4405-A3E4-14708EEB0112

P304

Q39174520-F95D62F5-B691-4349-9BEA-807D06FA4C45

P31

Q39174520-3614EAA7-220F-4506-B299-52B722C26A62

P356

Q39174520-736C60C6-BD1C-4E55-A99A-64285346A078

P407

Q39174520-88291E7C-3DB1-4C2E-8357-106B87CE94F9

P433

Q39174520-C23F50C2-BAFC-46B3-ACCC-E9839922488A

P478

Q39174520-4293B1B8-80BD-4C85-ADA9-2D8A6BA7AF76

P577

Q39174520-D49B1FAD-290D-432B-830A-BD41F1FCCB40

P5875

Q39174520-7AD3899C-94CD-4807-B515-826EF73C3018

P698

Q39174520-ABFA2E55-0923-40C6-B81F-2C2B558FD8CA

P932

Q39174520-D583CEFD-3DC0-4D39-8382-2E1403BA7980

P356

JIMMUNOL.1300271

P1433

Journal of Immunology

P1476

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

@en

P2093

Akgul Akpinarli

http://www.w3.org/2001/XMLSchema#string

Amy Fulton

http://www.w3.org/2001/XMLSchema#string

Aparna Baxi

http://www.w3.org/2001/XMLSchema#string

Koji Tamada

http://www.w3.org/2001/XMLSchema#string

Kristina M Harris

http://www.w3.org/2001/XMLSchema#string

Kyle A Wilson

http://www.w3.org/2001/XMLSchema#string

Paul Andrew Antony

http://www.w3.org/2001/XMLSchema#string

Scott E Strome

http://www.w3.org/2001/XMLSchema#string

Stephen R Goding

http://www.w3.org/2001/XMLSchema#string

Ying Xie

http://www.w3.org/2001/XMLSchema#string

P2860

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

T helper 17 cells promote cytotoxic T cell activation in tumor immunity

Tumor-specific Th17-polarized cells eradicate large established melanoma

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Restoring function in exhausted CD8 T cells during chronic viral infection

Cutting edge: TIGIT has T cell-intrinsic inhibitory functions

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

P304

4899-4909

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.1300271

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

190

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236088094

http://www.w3.org/2001/XMLSchema#string

P698

23536636

http://www.w3.org/2001/XMLSchema#string

P932

3633733

http://www.w3.org/2001/XMLSchema#string